ArticleJournal of medical virology2022
Omicron (B.1.1.529) variant of SARS-CoV-2: Concerns, challenges, and recent updates.
Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 86 citations in OpenAlex.
- Evaluation of SARS-CoV-2 Variants After the Declaration of End of COVID-19 Pandemic: BA.2.86 (Pirola) and EG.5 (Eris) Variants as Global Public Health Concerns.Health science reports · 2025Article
- Luteolin-Rich Extract fromLife (Basel, Switzerland) · 2025Article
- Reverse Zoonotic Transmission of SARS-CoV-2 and Monkeypox Virus: A Comprehensive Review.Journal of microbiology (Seoul, Korea) · 2024Review
- SARS-CoV-2 Omicron Spike shows strong binding affinity and favourable interaction landscape with the TLR4/MD2 compared to other variants.Journal, genetic engineering & biotechnology · 2024Article
- Molecular Epidemiology of Omicron CH.1.1 Lineage: Genomic and Phenotypic Data Perspective.Cureus · 2024Article
- COVID-19 and patients on renal replacement therapy: Perspective from the State of Qatar.Qatar medical journal · 2024Article
- Article
- Article
- The WHO has declared the end of pandemic phase of COVID-19: Way to come back in the normal life.Health science reports · 2023Article
- Can the RBD mutation R346X provide an additional fitness to the "variant soup," including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?Molecular therapy. Nucleic acids · 2023Article
- Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?Molecular therapy. Nucleic acids · 2023Article
- A global analysis of the effectiveness of policy responses to COVID-19.Scientific reports · 2023Article
- Efficient inactivation of the contamination with pathogenic microorganisms by a combination of water spray and plasma-activated air.Journal of hazardous materials · 2023Article
- Risk Stratification Model for Severe COVID-19 Disease: A Retrospective Cohort Study.Biomedicines · 2023Article
- Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report.Health science reports · 2023Article
- Evaluating Data Sharing of SARS-CoV-2 Genomes for Molecular Epidemiology across the COVID-19 Pandemic.Viruses · 2023Article
- Review
- Indian Biosimilars and Vaccines at Crossroads-Replicating the Success of Pharmagenerics.Vaccines · 2023Review
- Recent outbreak of Marburg virus disease: Could it be a threat for global public health?Health science reports · 2023Article
- From past to present: Exploring COVID-19 in Qatar's hemodialysis population across Omicron dominant and pre-Omicron periods.PloS one · 2023Observational
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.